tagitanlimab

Home
Ligands
tagitanlimab

GtoPdb Ligand ID: 13795

Synonyms: A-167 | Cotelet® | HBM-9167 | KL-A167 | KLA167

tagitanlimab is an approved drug

Comment: Tagitanlimab (KL-A167) is a humanized anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody [1]. It is designed to block the inhibitory PD-1/PD-L1 immune checkpoint and restore anti-tumour immunity.

Summary
Biological activity
Clinical data
References
Immunopharmacology

References
1. Shi Y, Qin X, Peng X, Zeng A, Li J, Chen C, Qiu S, Pan S, Zheng Y, Cai J et al.. (2023) Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study. Lancet Reg Health West Pac, 31: 100617. [PMID:36879786]

References

1. Shi Y, Qin X, Peng X, Zeng A, Li J, Chen C, Qiu S, Pan S, Zheng Y, Cai J et al.. (2023)
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study.
Lancet Reg Health West Pac, 31: 100617. [PMID:36879786]